Effect of pH on the Equilibrium Dialysis of Phenytoin Suspension with and without Enteral Feeding Formula

Abstract

Significant decreases have been reported in phenytoin absorption when the suspension is combined with continuous enteral feedings. Several theories for this interaction have been proposed including binding of phenytoin to the protein constituents of the enteral formula, phenytoin binding to the calcium in the enteral formula, and inadequate dissolution of the suspension when delivered with the enteral formula due to the high pKa of phenytoin and the acidic nature of the enteral formula. We therefore evaluated the effects of pH levels 2.0, 3.5, 6.0, and 8.0 on the interaction of phenytoin suspension with enteral formula (Osmolite) with equilibrium dialysis using a Spectra/Por 1 (MWCO 6000-8000) molecularporous dialysis membrane. Phenytoin concentrations in the dialysis membrane (internal phase) mimicked the expected stomach concentrations of a 100-mg dose administered in an adult stomach containing 200 ml of gastric fluid. External phase buffers were sampled at 0.5, 1.0, 2.0, 4.0, 8.0, 12.0, and 24.0 hr after the start of the dialysis. The phenytoin concentrations in the external phase were compared between buffer alone or buffer combined with enteral formula at the same pH and time intervals. With pH 2.0 and 3.5 the enteral formula formed an aggregate with suspension whereas no aggregate was formed with pH 6.0 and 8.0. The phenytoin concentrations with pH 2.0 were 26% to 44% lower and with pH 3.5 were 11.5 to 27% lower when phenytoin suspension was combined with enteral solution. However, at 24 hr there was no difference between the two conditions with both pH 2.0 and 3.5. With pH 6.0 there was a significant difference at 24 hr and with pH 8.0 significant differences were reached only at 0.5, 1.0 and 2.0 hr. These results show that the phenytoin suspension/enteral formula interaction is pH dependent. There appears to be a physical entrapment of the large suspension particles when the protein in the enteral solution denatures at lower pH's. These results may in part explain the decreased erratic absorption when phenytoin suspension is combined with enteral feedings. (Journal of Parenteral and Enteral Nutrition 14:275-278, 1990)

Get full access to this article

View all access options for this article.

References

Bauer LA : Interference of oral phenytoin absorption by continuous nasogastric feedings . Neurology 32:570-572, 1982

Evans WE , Schentag JJ , Jusko WJ (eds): Applied Pharmocokinetics Principles of Therapeutic Drug Monitoring . Applied Therapeutics, Inc., Spokane, WA, 1986.

Hatton RC : Dietary interaction with phenytoin (letter). Clin Pharm 3:110-111, 1984

Worden JR Jr , Wood CA Jr , Workman CH : Phenytoin and nasogastric feedings (letter) . Neurology 34:132, 1984

Longe RL , Smith OB : Phenytoin interaction with an oral feeding results in loss of seizure control . J Am Geriatrics Soc 36:542-544, 1988

Saklad JJ , Graves RH Sharp WP : Interaction of oral phenytoin with enteral feedings. JPEN 10:322-323. 1986

Ozuna J. Friel P. : Effect of enteral tube feeding on serum phenytoin levels. Am Assoc Neuroscience Nutr 16:289-91, 1984

Krueger KA Garnett WR , Comstock TJ et al: Effect of two administration schedules of an enteral nutrient formula on pheny-toin bioavailability. Epilepsia 28:706-712, 1987

Cacek AT De Vito JM , Koonce JR : In vitro evaluation of nasogastric administration methods for phenytoin . Am J Hosp Pharm 43:689-692, 1986

10.

Hooks MA , Longe RL , Taylor AT , et al: Recovery of phenytoin from an enteral nutrient formula. Am J Hosp Pharm 43:685-688, 1986

11.

Nishimura LY , Armstrong EP , Plezia PM , et al: Influence of enteral feedings on phenytoin sodium absorption from capsules. Drug Intell Clin Pharm 22:130-133, 1988

12.

Smith OB , Longe RL , Altman RE , et al: Recovery of phenytoin from solutions of caseinate salts and calcium chloride. Am J Hosp Pharm 45:365-367, 1988

13.

Rodbro P. , Krasilnikoff PA , Bitsch V. : Gastric secretion of pepsin in early childhood. Scand J Gastroenterol 2:257-260, 1967

14.

Campbell JW , Frisse M , (eds): Manual of Medical Therapeutics, 24th ed. Little, Brown and Company, Boston, MA, 1983

15.

Splinter MY , Seifert CF , Bradberry JC , et al: The recovery of phenytoin suspension after in vitro administration through percutaneous endoscopic gastrostomy pezzar catheters. Am J Hosp Pharm 47:373-377, 1990

16.

Runyon RP : Fundamentals of Statistics in the Biological, Medical and Health Sciences . Duxbury Press, Boston, 1985

17.

Miller I. , Freund JE : Probability and Statistics for Engineers. Prentice-Hall, Inc., Englewood Cliffs, NJ, 1965

18.

Woodbury DM , Penry JK , Pippenger CE (eds): Antiepileptic Drugs, 2nd ed. Raven Press, New York, 1982

19.

Kulshiestha VK , Thomas M. , Wadsworth J. , et al: Interaction between phenytoin and antacids. Br J Clin Pharmacol 6:177-179, 1978

20.

Garnett WR , Carter BL , Pellock JM : Bioavailability of phenytoin administered with antacids. Ther Drug Monitor 1:435-436, 1979

21.

Cacek AT : Review of alterations in oral phenytoin bioavailability associated with formulation, antacids, and food. Ther Drug Monitor 8:166-171, 1986

22.

Hatton RC : Dietary interaction with Phenytoin (letter). Clin Pharm 3:110-111, 1984

23.

Zuerker JC , Bradberry JC , Seifert CF , et al: Medications for use in patients with enteral feeding tubes (letter) . Gastrointest Endoscopy 33:127, 1987